Douglas Blankenship
2017
In 2017, Douglas Blankenship earned a total compensation of $1.6M as Former Chief Financial Officer at Dova Pharmaceuticals.
Compensation breakdown
| Option Awards | $1,357,551 |
|---|---|
| Salary | $208,526 |
| Other | $1,042 |
| Total | $1,567,119 |
Blankenship received $1.4M in option awards, accounting for 87% of the total pay in 2017.
Blankenship also received $208.5K in salary and $1K in other compensation.
Rankings
In 2017, Douglas Blankenship's compensation ranked 6,756th out of 14,666 executives tracked by ExecPay. In other words, Blankenship earned more than 53.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,756 out of 14,666 | 54th |
Division Manufacturing | 2,504 out of 5,772 | 57th |
Major group Chemicals And Allied Products | 811 out of 2,075 | 61st |
Industry group Drugs | 626 out of 1,731 | 64th |
Industry Pharmaceutical Preparations | 493 out of 1,333 | 63rd |
Source: SEC filing on April 27, 2018.
Blankenship's colleagues
We found two more compensation records of executives who worked with Douglas Blankenship at Dova Pharmaceuticals in 2017.